Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

NCT04563195 is registered in ClinicalTrials.gov with Matthew C. Baker as lead sponsor.

NCT NCT04563195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04563195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Lead sponsor
Matthew C. Baker
Phase
Phase 2/3
Overall status
Withdrawn
Start date
February 1, 2022
Completion date
January 31, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjogren's syndrome